On January 12, Suneva Medical Inc. and Viveon Health Acquisition Corp. announced a definitive merger agreement for the two companies with the combined company’s securities to be traded on the NYSE as “RNEW.” Approved by the boards of directors for both Suneva and Viveon, the merger, expected to be completed in the first half of 2022, is subject to approval of each company's stockholders and of regulatory approval.
Suneva is a pure-play regenerative aesthetics company that developes, manufactures, and sells products using minimally invasive solutions for outpatient treatment to achieve immediate aesthetic results. The regenerative aesthetics market is one of the fastest growing sectors of the aesthetics market, and the parties believe the transaction will help address increasing patient demand for such treatments.